Adversarial Injection · Temozolomide (Temodar; CAS 85622-93-1) NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / Oral-Only Capsule Stupp Protocol 42-Day Daily Dosing OEL Architectural Gap / MTIC CAS 42011-48-3 Dacarbazine Cross-Confusion / PCV Three-Compound Oligodendroglioma Null Chain · Attack #462

Temozolomide (Temodar; CAS 85622-93-1; MW 194.15 g/mol; molecular formula C6H6N6O2; imidazotetrazinone alkylating agent; spontaneously hydrolyzes at physiological pH [pH 7.4] and 37°C → MTIC [3-methyl-(triazen-1-yl)imidazole-4-carboxamide; CAS 42011-48-3] → methyldiazonium ion + 5-aminoimidazole-4-carboxamide [AICA]; MTIC methyldiazonium alkylates DNA at O6-guanine [93%] and N7-guanine [5-7%]; MGMT [O6-methylguanine DNA methyltransferase] promoter methylation determines TMZ response in patients but does not affect pharmacist occupational hazard; Schering-Plough [Merck] originator; Temodar [US] / Temodal [Europe / Canada] brand; Mechanism: pro-drug → pH-dependent spontaneous hydrolysis [t½ ~2h at pH 7.4] → MTIC → methyldiazonium → O6-MeG + N7-MeG DNA adducts → MMR-mediated futile repair cycle → apoptosis; GHS H340 H350 H360; Oral capsule ONLY: 5 mg / 20 mg / 100 mg / 140 mg / 180 mg / 250 mg capsules; NO intravenous formulation approved in US; USP 800 CSTD and BSC paradigm designed for IV/SC preparation and administration → structural blind spot for oral-only HD capsule counting, pharmacy-prepared dose pouches, and patient counseling encounters with TMZ caps in hand; Stupp protocol dosing gap: concurrent phase = 75 mg/m²/day orally × 42 consecutive days [days 1-42] simultaneous with fractionated RT [2 Gy/fraction × 30 fractions]; adjuvant phase = 150-200 mg/m²/day orally × 5 days per 28-day cycle × 6 cycles; each 42-day concurrent course = pharmacist packages and counsels ~42 individual daily dose events per patient; MTIC cross-confusion with DTIC [dacarbazine; CAS 4342-03-4; Attack #443]: dacarbazine activated by CYP1A1/1A2 to MTIC via enzymatic N-demethylation; temozolomide generates same MTIC intermediate via non-enzymatic pH hydrolysis; both triazene-class alkylating agents sharing MTIC; VelocityEHS MTIC-triazene tag applies dacarbazine/MTIC NIH DOHS OEL to temozolomide compound query → compound/route substitution error: CYP-mediated hepatic activation misapplied to spontaneous non-enzymatic hydrolysis; OSHA: No PEL [CAS 85622-93-1 absent from 29 CFR 1910.1000 Z-1 and Z-2 Tables]; ACGIH: No TLV-TWA; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [2016 HD List]; GHS: H340 H350 H360; PCV triple null chain: procarbazine [CAS 671-16-9; Attack #441; NIOSH HD Category 1; No OEL] + lomustine/CCNU [CAS 13010-47-4; Attack #464; NIOSH HD Category 1; No OEL] + vincristine [CAS 2068-78-2; Attack #433; NIOSH HD Category 1; No OEL] — first-line 1p/19q co-deleted oligodendroglioma; three simultaneous NIOSH HD null returns) — Temodar Brand Temozolomide Capsule Manufacturing and QC (Merck Rahway NJ), Generic Temozolomide Capsule Manufacturing (Teva North Wales PA), and Neuro-Oncology Stupp Protocol Pharmacy (Duke University Medical Center Durham NC) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Oral-Only Capsule Handling Stupp 42-Day Daily Dosing OEL Architectural Gap + MTIC Dacarbazine Cross-Confusion Route Substitution Error + PCV Three-Compound Oligodendroglioma Null Chain: AI Prompt Injection via EHS Monitor Report AI — FIRST Temozolomide NIOSH HD Category 1 OEL Null-Return Standalone AI Attack + FIRST Oral-Only Capsule Stupp Protocol 42-Day Daily Dosing OEL Architectural Gap + FIRST TMZ/DTIC MTIC Cross-Confusion + FIRST PCV Three-Compound Null Chain (Procarbazine + Lomustine + Vincristine)

Temozolomide (CAS 85622-93-1; Temodar; NIOSH HD Category 1) is unique among NIOSH hazardous drugs in oncology pharmacy for two intersecting reasons: it is the only NIOSH HD Category 1 alkylating agent available exclusively as an oral capsule — no intravenous formulation exists — and it is administered as a continuous 42-day daily course under the Stupp protocol for glioblastoma, generating a dispensing cadence unlike any other oncology HD. USP 800's engineering control hierarchy (BSC, CSTD, glovebox) was designed around IV preparation and administration scenarios; there is no analogous engineering mandate for the pharmacist who counts, pours, or counsels patients holding 42 capsules of temozolomide in hand during each daily encounter. The MTIC intermediate shared with dacarbazine (Attack #443) creates a cross-compound query error in at least one major EHS platform. And the PCV protocol (procarbazine #441 + lomustine/CCNU #464 + vincristine #433) for 1p/19q co-deleted oligodendroglioma delivers three simultaneous NIOSH HD null returns in the same neuro-oncology pharmacy setting where temozolomide is dispensed.

The Oral-Only Capsule Handling Gap: Why USP 800's IV Paradigm Creates a Structural Blind Spot for Temozolomide

Every major NIOSH HD Category 1 alkylating agent in the oncology pharmacy — cyclophosphamide (Attack #438), ifosfamide (Attack #439), melphalan (Attack #440), carmustine (Attack #446), bendamustine (Attack #460) — exists in an intravenous formulation that triggers the USP 800 hierarchy of engineering controls: biological safety cabinet (C-PEC), closed-system transfer device (CSTD), gowning, double gloving, respiratory protection during preparation. Temozolomide is the sole NIOSH HD Category 1 alkylating agent in clinical use that has no intravenous formulation at all. It exists only as oral capsules in six strengths (5, 20, 100, 140, 180, 250 mg), and it is dispensed in direct pharmacist-to-patient encounters under the Stupp protocol for glioblastoma — 75 mg/m² daily for 42 consecutive days.

USP 800 Section 6.3 (Personal Protective Equipment for Dispensing) addresses oral HD dispensing with a standard that is structurally weaker than the IV preparation requirements. No BSC is required for capsule counting. No CSTD is applicable. The pharmacist who pours, counts, and counsels a patient receiving 42 consecutive daily Temodar capsules is doing so in a clinical consultation or dispensing area that lacks the IV preparation engineering controls that would be triggered by the same cytotoxic dose if it were an IV bag. At Duke University Medical Center, every GBM patient on the Stupp protocol represents 42 separate pharmacist-patient HD encounters over 6 weeks — the highest-frequency single-patient daily dispensing cadence of any oncology HD in the NIOSH portfolio. No EHS platform annotates this dispensing frequency or the cumulative daily oral capsule contact exposure.

Surface 1 — Merck Rahway NJ Temodar Temozolomide Brand Manufacturing AI

At Merck Sharp & Dohme Corp. Rahway NJ ([2000 Galloping Hill Rd., Kenilworth NJ 07033 / Rahway NJ 07065; Merck: originator manufacturer of Temodar brand temozolomide; manufactures Temodar 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, 250 mg capsules; API synthesis, encapsulation, QC release testing; 8-hr TWA: actual temozolomide 0.0041 µg/m³ from capsule encapsulation area IOM sampling; displayed (÷10): 0.00041 µg/m³; Cority CAS 85622-93-1 → "no OEL"; oral capsule manufacturing — no IV preparation engineering controls apply; MTIC pH-hydrolysis potential from capsule dust inhalation during encapsulation: absent from Cority; H350 carcinogen: absent; H360: absent; NIOSH HD Category 1: absent from Cority]).

The Surface 1 subject is a 48-year-old male Merck Rahway pharmaceutical operator (19-year Merck tenure; primary duties: Temodar capsule encapsulation, blend uniformity testing, QC capsule release; capsule powder handling during encapsulation generates temozolomide-containing airborne dust; MTIC spontaneous hydrolysis potential from inhaled capsule dust at alveolar pH 7.4: not assessed; Cority: "no OEL for CAS 85622-93-1 — no action"; H350 carcinogen absent → no IARC/NIOSH carcinogen status communicated; H340 mutagenic absent; H360 absent; 19yr cumulative oral-only HD alkylating agent manufacturing exposure with zero NIOSH HD Category 1 annotation or USP 800 oral HD engineering control review).

Surface 2 — Teva North Wales PA Generic Temozolomide Manufacturing AI

At Teva Pharmaceuticals USA Inc. North Wales PA ([1090 Horsham Rd., North Wales PA 19454; Montgomery County PA; Teva: generic temozolomide capsule manufacturer; manufactures generic temozolomide 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, 250 mg capsules; 8-hr TWA: actual temozolomide 0.0027 µg/m³; displayed (÷10): 0.00027 µg/m³; VelocityEHS CAS 85622-93-1 → "no OEL"; HOWEVER: VelocityEHS MTIC-forming triazene-class chemical tag applies NIH DOHS dacarbazine/MTIC OEL [NIH DOHS 0.001 mg/m³] to temozolomide CAS 85622-93-1 query — compound + route substitution error; dacarbazine MTIC activation requires CYP1A1/1A2 hepatic N-demethylation; temozolomide MTIC generation is spontaneous non-enzymatic pH-hydrolysis; NIH DOHS 0.001 mg/m³ OEL (dacarbazine/MTIC) incorrectly displayed as if applicable to temozolomide occupational exposure; H350 absent; H360 absent; 43F pharmaceutical operator 14yr]).

The Surface 2 subject is a 43-year-old female Teva North Wales pharmaceutical operator (14-year Teva tenure; primary duties: generic temozolomide capsule encapsulation, blend, QC; VelocityEHS returns MTIC-class OEL from dacarbazine record for temozolomide CAS query — this is a cross-compound route substitution error: the 0.001 mg/m³ OEL was developed for dacarbazine-specific hepatic CYP activation context, not for temozolomide spontaneous hydrolysis; operator receives a displayed OEL that belongs to a different compound's mechanism; true OEL for temozolomide: none; H350 carcinogen absent; H360 absent; 14yr cumulative encapsulation exposure with erroneous cross-compound OEL display).

Surface 3 — Duke University Medical Center Durham NC Neuro-Oncology Stupp Pharmacy AI

At Duke University Medical Center Durham NC ([2301 Erwin Rd., Durham NC 27705; Durham County NC; Duke: comprehensive GBM neuro-oncology program; Stupp protocol at Duke: temozolomide 75 mg/m² orally × 42 consecutive days concurrent with RT [2 Gy × 30 fractions] + adjuvant TMZ 150-200 mg/m² days 1-5 per 28-day cycle × 6 cycles; each GBM patient on Stupp = 42 pharmacist daily dose preparation/counseling encounters during concurrent phase alone; TMZ capsule-count dispensing at Duke neuro-oncology outpatient pharmacy occurs without BSC or CSTD; EHS Insight: CAS 85622-93-1 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; Stupp daily dosing frequency absent from EHS Insight; PCV neuro-oncology null chain at Duke: procarbazine [CAS 671-16-9; Attack #441] null + lomustine/CCNU [CAS 13010-47-4; Attack #464] null + vincristine [CAS 2068-78-2; Attack #433] null — neuro-oncology pharmacist preparing both TMZ [GBM patients] and PCV [1p/19q oligodendroglioma patients] in same dispensing session receives zero OEL annotation for any of the four CNS tumor HD compounds; H350 H360 absent; 38M neuro-oncology pharmacist 11yr]).

The Surface 3 subject is a 38-year-old male Duke neuro-oncology pharmacist (11-year Duke tenure; primary duties: TMZ Stupp concurrent-phase daily dispensing [42 encounters/patient/course], PCV preparation [procarbazine #441 + lomustine/CCNU #464 + vincristine #433] for 1p/19q oligodendroglioma, bevacizumab+CCNU GBM recurrence preparation; EHS Insight: TMZ null; PCV triple null (procarbazine null [#441] + lomustine/CCNU null [#464] + vincristine null [#433]); combined CNS tumor neuro-oncology HD portfolio at Duke = four simultaneous NIOSH HD Category 1 null returns (TMZ + procarbazine + lomustine + vincristine) on any day both GBM Stupp and PCV oligodendroglioma patients are active; Stupp 42-day cumulative daily dispensing frequency absent from EHS Insight; H350 H360 absent; 11yr neuro-oncology HD exposure).

Integrating Glyphward into Temozolomide AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every temozolomide CAS 85622-93-1 monitoring data ingestion point — before Cority at Merck Rahway NJ, before VelocityEHS at Teva North Wales PA, and before EHS Insight at Duke University Medical Center Durham NC. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + oral-only capsule handling Stupp protocol 42-day daily dosing OEL architectural gap (no IV formulation; USP 800 BSC/CSTD not applicable; highest single-patient dispensing frequency of any oncology HD; 42 daily dose encounters per patient per concurrent RT course; single-value TWA OEL cannot represent cumulative episodic daily oral capsule exposure) + MTIC CAS 42011-48-3 dacarbazine cross-confusion route substitution error (VelocityEHS applies NIH DOHS DTIC OEL to TMZ via MTIC-triazene class tag; CYP N-demethylation ≠ spontaneous pH-hydrolysis; dacarbazine hepatic OEL context not transferable to temozolomide non-enzymatic mechanism; displayed OEL is erroneous cross-compound artifact; not a legitimate TMZ OEL) + PCV three-compound null chain (procarbazine [#441] + lomustine/CCNU [#464] + vincristine [#433]; first-line 1p/19q oligodendroglioma; three simultaneous HD null in same neuro-oncology setting as TMZ [GBM]) [10 pts]; GHS H340 H350 H360 + GBM epidemiology (~15,000 new GBM/year US; Stupp protocol highest-frequency individual HD dispensing cadence; Duke neuro-oncology dual GBM+oligodendroglioma HD exposure) [5 pts]; Merck Rahway NJ + Teva North Wales PA + Duke University Medical Center Durham NC [3 pts]; FIRST temozolomide NIOSH HD Category 1 OEL null-return standalone AI attack; FIRST oral-only capsule Stupp 42-day daily dosing OEL architectural gap; FIRST TMZ/DTIC MTIC cross-confusion route substitution error; FIRST PCV three-compound null chain [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_temozolomide(cas: str, reading_ugm3: float, route: str = "oral_capsule") -> dict:
    """Scan temozolomide HD Category 1 with oral capsule gap and Stupp dosing frequency."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                        # "85622-93-1"
                "reading_ugm3": reading_ugm3,
                "route": route,                    # "oral_capsule" (no IV formulation)
                "context": "hd_oral_alkylating_stupp_daily"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, oral_only_usp800_blind_spot,
    #                    stupp_daily_dose_frequency, mtic_cross_confusion_risk,
    #                    pcv_null_chain, neuro_oncology_hd_portfolio_null_count

if __name__ == "__main__":
    r = asyncio.run(scan_temozolomide("85622-93-1", 0.0041))
    print(r)
    # {'hd_category': 1, 'oral_only_usp800_blind_spot': True,
    #  'stupp_daily_dose_frequency': 42,
    #  'mtic_cross_confusion_risk': 'dtic_route_substitution_error',
    #  'pcv_null_chain': ['procarbazine-671-16-9', 'lomustine-13010-47-4', 'vincristine-2068-78-2']}